

14. A <sup>method</sup>~~composition~~ according to claim <sup>34</sup>~~10~~, wherein said one or more LHRH analogues is a non-peptidergic LHRH agonist or non-peptidergic LHRH antagonist.

15. A <sup>method</sup>~~composition~~ according to claim <sup>34</sup>~~10~~, wherein anti-estrogen is Raloxifen, Droloxifen, or Centchroman.

16. A <sup>method</sup>~~composition~~ according to claim <sup>34</sup>~~10~~, wherein said anti-estrogen is Raloxifen.

17. A method for treating a gynecological disorder comprising administering one or more LHRH analogues, and at least one anti-estrogen having tissue-selective estrogenic activity.

18. A method according to claim 17, wherein said LHRH analogue and anti-estrogen are administered sequentially.

19. An article of manufacture comprising two spatially separately packaged active ingredients, one of which is at least one LHRH analogue and the other of which is an anti-estrogen having tissue-selective estrogen activity.

20. A <sup>method</sup>~~composition~~ according to claim <sup>34</sup>~~10~~, wherein said LHRH analogue is an LHRH antagonist.

21. A <sup>method</sup>~~composition~~ according to claim <sup>35</sup>~~10~~, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, or Zoladex and said anti-estrogen is Raloxifen, Droloxifen, or Centchroman.

22. A <sup>method</sup>~~composition~~ according to claim <sup>34</sup>~~10~~, wherein said anti-estrogen is a selective estrogen-receptor modulator.

23. A method according to claim 17, wherein said gynecological disorder is endometrioses.

RECEIVED  
FEB 16 2000  
C 1700 MAIL ROOM

24. A method according to claim 17, wherein said gynecological disorder is myomas.
25. A method according to claim 17, wherein said LHRH analogue and said anti-estrogen are administered simultaneously.
26. A method according to claim 18, wherein said anti-estrogen is administered after administration of said LHRH analogue.
27. A method according to claim 17, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, Zoladex or combinations thereof and said anti-estrogen is Raloxifen, Droloxifen, Centchroman or combinations thereof.
28. A method according to claim 18, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, Zoladex or combinations thereof and said anti-estrogen is Raloxifen, Droloxifen, Centchroman or combinations thereof.
29. A method according to claim 26, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, Zoladex or combinations thereof and said anti-estrogen is Raloxifen, Droloxifen, Centchroman or combinations thereof.
30. A method according to claim 17, wherein said LHRH analogue is administered in the amount of 2 µg-20 mg per kilogram of body weight and said anti-estrogen is administered in an amount of 0.1 µg-10 mg per kilogram of body weight.
31. An article of manufacture according to claim 19, further comprising an information leaflet on the simultaneous, sequential or both simultaneous and sequential administration.

213  
32. An article of manufacture according to claim 19, wherein Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, or Zoladex and said anti-estrogen is Raloxifen, Droloxifen, or Centchroman.

D<sub>1</sub> 33. An article of manufacturing according to claim 19, wherein said LHRH analogue is peptidergic.

C<sub>1</sub>  
Cont  
P<sub>1</sub>  
H<sub>2</sub>  
34. A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and at least one anti-estrogen wherein said one or more LHRH analogues and said at least one anti-estrogen are administered sequentially or simultaneously.

35. A method according to claim 34, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, Zoladex or combinations thereof and said anti-estrogen is Raloxifen, Droloxifen, Centchroman or combinations thereof.

36. A method according to claim 34, wherein said anti-estrogen is administered after administration of said LHRH analogue.

37. A method of inhibiting side effects associated with administration of an LHRH analogue comprising administering at least one anti-estrogen and one or more LHRH analogues, wherein administration is sequential or simultaneous.

38. A method according to claim 37, wherein said LHRH analogue is Leuporelin, Cetrorelix, Buserelin, Antide, Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH<sub>2</sub>, Ramorelix, Zoladex or combinations thereof and said anti-estrogen is Raloxifen, Droloxifen, Centchroman or combinations thereof.

39. A method according to claim 37, wherein said anti-estrogen is administered after administration of said LHRH analogue.--